CELG - Celgene's Long Journey Through Regulatory Filings For Ozanimod Might Finally Pay Off
Celgene (CELG) is in good shape in terms of its multiple sclerosis ((MS)) drug ozanimod. That's because it announced that regulatory applications for the drug was accepted by both the FDA and EMA. This gives the company the potential to obtain approval for both territories. Getting this product filed with regulatory agencies has been a tough road for Celgene, because its first application to file for regulatory approval was refused by the FDA. The company is on the right track now.
Regulatory Applications Finally Accepted For Review
The FDA accepted the application for